In North America, ABVD has been a standard approach in Hodgkin lymphoma therapy since the 1970s; however, three recent advances – PET imaging, brentuximab vedotin, and PD-1 blockade – are significantly altering treatment strategies. Recognition of the prognostic significance of interim PET has led to PET-adapted treatment approaches, which identify patients who might benefit from therapy escalation or de-escalation. Brentuximab vedotin and PD-1 blockade have improved outcomes in the relapsed and refractory setting, but their ideal place in the management of Hodgkin lymphoma is unclear. This session will focus on PET-adapted therapy and incorporation of the newer drugs for Hodgkin lymphoma, in both frontline and relapsed/refractory settings.
Dr. Ranjana Advani will summarize recent advances in the frontline treatment of advanced-stage Hodgkin lymphoma. She will discuss response-adapted therapy and the role of novel agents in patients with newly diagnosed advanced stage disease.
Dr. Alison Moskowitz will discuss the ideal settings for use of brentuximab vedotin in Hodgkin lymphoma. She will review the data supporting approved and investigational uses.
Dr. Alex Herrera will discuss the role of PD-1 inhibitors in the treatment of Hodgkin lymphoma. He will review the data supporting approved indications for PD-1 blockade and discuss investigational combinations.
Ranjana Advani, MD
Alison Moskowitz, MD
Alex Herrera, MD
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members